Skip to main content

MINI REVIEW article

Front. Immunol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1509987
This article is part of the Research Topic Reviews in: Multiple Sclerosis and Neuroimmunology View all 8 articles

The immunological bases of alemtuzumab as inductiontherapies in pediatric-onset multiple sclerosis

Provisionally accepted
Marco Puthenparampil Marco Puthenparampil 1,2,3*Marta Gaggiola Marta Gaggiola 1Francesca Rinaldi Francesca Rinaldi 2Margherita Nosadini Margherita Nosadini 3,4Stefano Sartori Stefano Sartori 3,4Paola Perini Paola Perini 2Paolo Gallo Paolo Gallo 1,2
  • 1 Department of Neuroscience, School of Medicine and Surgery, University of Padua, Padua, Italy
  • 2 Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy, Padova, Italy
  • 3 Neuroimmunology Group, Paediatric Research Institute "Città della Speranza", Padua, Italy
  • 4 Paediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, School of Medicine and Surgery, University of Padua, Padova, Italy

The final, formatted version of the article will be published soon.

    Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALTZ), might be a promising approach, at least for postpuberal (> 11 yo) POMS. Although no data on the use of induction therapies in POMS are available from clinical trials currently, case series or case reports on the effect of alemtuzumab (ALTZ) have been recently published. In this review we have briefly revised the immunopathogenic features of POMS, as well as on how ALTZ might impact on them, reporting its efficacy observed in different POMS cohorts.

    Keywords: pediatric-onset MS, POMS, alemtuzumab, Induction therapy, Multiple Sclerosis

    Received: 11 Oct 2024; Accepted: 18 Dec 2024.

    Copyright: © 2024 Puthenparampil, Gaggiola, Rinaldi, Nosadini, Sartori, Perini and Gallo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Marco Puthenparampil, Department of Neuroscience, School of Medicine and Surgery, University of Padua, Padua, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.